- Home
- CYH vs CRMD Comparison
CYH vs CRMD Comparison
Compare CYH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- CRMD
- Stock Information
- Founded
- CYH 1985
- CRMD 2006
- Country
- CYH United States
- CRMD United States
- Employees
- CYH N/A
- CRMD N/A
- Industry
- CYH Hospital/Nursing Management
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- CRMD Health Care
- Exchange
- CYH Nasdaq
- CRMD Nasdaq
- Market Cap
- CYH 440.4M
- CRMD 753.6M
- IPO Year
- CYH 1991
- CRMD 2010
- Fundamental
- Price
- CYH $3.20
- CRMD $10.15
- Analyst Decision
- CYH Hold
- CRMD Strong Buy
- Analyst Count
- CYH 6
- CRMD 6
- Target Price
- CYH $4.40
- CRMD $15.67
- AVG Volume (30 Days)
- CYH 1.9M
- CRMD 1.5M
- Earning Date
- CYH 02-18-2025
- CRMD 03-11-2025
- Dividend Yield
- CYH N/A
- CRMD N/A
- EPS Growth
- CYH N/A
- CRMD N/A
- EPS
- CYH N/A
- CRMD N/A
- Revenue
- CYH $12,551,000,000.00
- CRMD $12,262,234.00
- Revenue This Year
- CYH $1.16
- CRMD N/A
- Revenue Next Year
- CYH $1.18
- CRMD $246.41
- P/E Ratio
- CYH N/A
- CRMD N/A
- Revenue Growth
- CYH 0.81
- CRMD 41184.20
- 52 Week Low
- CYH $2.51
- CRMD $2.89
- 52 Week High
- CYH $6.29
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- CYH 45.86
- CRMD 40.80
- Support Level
- CYH $3.20
- CRMD $11.90
- Resistance Level
- CYH $3.39
- CRMD $12.67
- Average True Range (ATR)
- CYH 0.16
- CRMD 0.73
- MACD
- CYH 0.02
- CRMD -0.27
- Stochastic Oscillator
- CYH 47.14
- CRMD 2.12
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.